FDA News

FDA Biosimilar User Fee Rates: Fiscal Year 2016

In order to expedite the review process of biosimilar biological products, FDA is authorized to assess and collect fees from sponsors. The fees are collected for various activities related to biosimilar biological product development (BPD), including: Initial and annual BPD... Read More